


Product Name : PX-866
Cat. No. : PC-27224
CAS No. : 502632-66-8
Molecular Formula : C₂₉H₃₅NO₈
Molecular Weight : 525.60
Target : PI3K
Solubility : 10 mM in DMSO



Biological Activity

Sonolisib (PX-866) is a Wortmannin analogue and an oral, irreversible, and pan-isoform PI3K inhibitor with IC₅₀ of 0.1 nM, 1.0 nM and 2.9 nM for p110 α , p120 γ and p110 δ .

Sonolisib (PX-866) inhibits PI3-kinase signaling measured by phospho-Ser473-Akt levels in HT-29 colon cancer cells with IC₅₀ of 20 nM.

Sonolisib (PX-866) at 10 mg/kg inhibited phospho-Ser473-Akt in HT-29 colon tumor xenografts up to 80% with recovery taking >48 hours after p.o. administration but more rapidly after i.v. or i.p. administration.

Sonolisib (PX-866) exhibited in vivo antitumor activity against s.c. OvCar-3 human ovarian cancer and A-549 human lung cancer xenografts in immunodeficient mice.

References

Ihle NT, et al. Mol Cancer Ther. 2004 Jul;3(7):763-72.

Ihle NT, et al. Mol Cancer Ther. 2005 Sep;4(9):1349-57.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com